Keyphrases
CDC6
100%
Prostate Cancer
100%
GATA2
100%
Induced Senescence
100%
Androgen Receptor Blockade
100%
Senescence
81%
Enzalutamide
45%
Androgen-independent
36%
Epithelial-to-mesenchymal Transition
18%
LNCaP
18%
C4-2B
18%
Tumor Progression
9%
Oncogene
9%
Cancer Development
9%
Mouse Xenograft
9%
Invasive Potential
9%
Repressor
9%
RNA Interference
9%
Bioinformatics Analysis
9%
Replication Licensing Factors
9%
Detrimental Effects
9%
Abrogation
9%
Cancer Causes
9%
Cancer Mortality
9%
Disease Progression
9%
Immunocytochemistry
9%
Confocal Microscopy
9%
Resistant Cells
9%
Androgens
9%
Path Analysis
9%
RNA-seq Analysis
9%
Signaling Axis
9%
PC-3 Cells
9%
Therapeutic Window
9%
Treatment Responsiveness
9%
Direct Inhibitors
9%
Castration-resistant Prostate Cancer
9%
Androgen Receptor Antagonist
9%
Acquired Resistance
9%
Cancer Morbidity
9%
LNCaP Cells
9%
Senescence Induction
9%
Transition Marker
9%
Highly Aggressive
9%
Androgen Deprivation Therapy
9%
Resistant Prostate Cancer
9%
Resistance to Therapy
9%
Sensitive Diseases
9%
Induced Models
9%
Prostate Cancer Progression
9%
Cancer Ecosystem
9%
Endogenous Activation
9%
GATA2 Transcription Factor
9%
Biochemistry, Genetics and Molecular Biology
Receptor Blocking
100%
Androgen Receptor
100%
GATA2
100%
Enzalutamide
83%
LNCaP
50%
Mesenchymal-Epithelial Transition
33%
Tumor Progression
16%
Repressor
16%
RNA Interference
16%
Downregulation
16%
Oncogene
16%
Immunocytochemistry
16%
Confocal Microscopy
16%
RNA Sequence
16%